Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in indolent systemic mastocytosis
2024-512585-34-00Phase 2Authorised
- Sponsor
- Blueprint Medicines
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in indolent systemic mastocytosis (ISM) comparing Avapritinib with Placebo (2 arms). Primary endpoints: Recommended phase 2 dose, Change in ISM-SAF total symptom score and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
avapritinib
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on 2024-512585-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512585-34-00.